Compare BLNK & ACIU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BLNK | ACIU |
|---|---|---|
| Founded | 2009 | 2003 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Industrial Specialties | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 86.2M | 247.6M |
| IPO Year | 2008 | 2015 |
| Metric | BLNK | ACIU |
|---|---|---|
| Price | $0.53 | $2.66 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 4 | 2 |
| Target Price | $2.33 | ★ $10.00 |
| AVG Volume (30 Days) | ★ 1.1M | 180.6K |
| Earning Date | 05-08-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 61.22 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $126,197,000.00 | N/A |
| Revenue This Year | $5.71 | $706.75 |
| Revenue Next Year | $19.65 | $321.13 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.45 | $2.10 |
| 52 Week High | $2.65 | $4.00 |
| Indicator | BLNK | ACIU |
|---|---|---|
| Relative Strength Index (RSI) | 43.68 | 53.18 |
| Support Level | $0.51 | $2.57 |
| Resistance Level | $0.62 | $3.00 |
| Average True Range (ATR) | 0.03 | 0.12 |
| MACD | -0.00 | -0.02 |
| Stochastic Oscillator | 27.17 | 35.71 |
Blink Charging Co is an owner, operator, and provider of electric vehicle (EV) charging services. The company offers both residential and commercial EV charging equipment, enabling EV drivers to easily recharge at various location types. The Blink's principal line of products and services is its Blink EV charging networks, Blink EV charging equipment, and other EV-related services. The Blink Network is a proprietary, cloud-based system that operates, maintains, and manages Blink charging stations and handles the associated charging data, back-end operations, and payment processing. The Blink Network provides fleets, property owners, managers, parking companies, and state and municipal entities, among other types of commercial customers, with cloud-based services.
AC Immune SA is a clinical stage biopharmaceutical company advancing a portfolio of programs strategically focused on pioneering Precision Medicine for neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company has one segment. The company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.